Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Hallek, B. Cheson, D. Catovsky, F. Caligaris‐cappio, G. Dighiero, H. Döhner, P. Hillmen, M. Keating, E. Montserrat, K. Rai, T. Kipps (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.Blood, 111 12
J. Byrd, Jennifer Brown, S. O'brien, J. Barrientos, N. Kay, N. Reddy, S. Coutre, C. Tam, S. Mulligan, U. Jaeger, S. Devereux, P. Barr, R. Furman, T. Kipps, F. Cymbalista, C. Pocock, P. Thornton, F. Caligaris‐cappio, T. Robak, J. Delgado, S. Schuster, M. Montillo, A. Schuh, S. Vos, D. Gill, A. Bloor, C. Dearden, C. Moreno, Jeffrey Jones, A. Chu, M. Fardis, J. Mcgreivy, F. Clow, D. James, P. Hillmen (2014)
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.The New England journal of medicine, 371 3
(2012)
lymphocytes [ letter ]
Jennifer Brown, J. Barrientos, P. Barr, I. Flinn, J. Burger, A. Tran, F. Clow, D. James, T. Graef, J. Friedberg, K. Rai, S. O'brien (2015)
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.Blood, 125 19
M. Oken, R. Creech, D. Tormey, J. Horton, T. Davis, E. McFadden, P. Carbone (1982)
Toxicity and response criteria of the Eastern Cooperative Oncology GroupAMERICAN JOURNAL OF CLINICAL ONCOLOGY, 5
M. Hallek, N. Pflug (2019)
Chronic Lymphocytic LeukemiaAnnals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 7
S. O'brien, R. Furman, S. Coutre, J. Sharman, J. Burger, K. Blum, B. Grant, D. Richards, M. Coleman, W. Wierda, Jeffrey Jones, Weiqiang Zhao, N. Heerema, A. Johnson, R. Izumi, A. Hamdy, B. Chang, T. Graef, F. Clow, J. Buggy, D. James, J. Byrd (2014)
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.The Lancet. Oncology, 15 1
J. Byrd, R. Furman, S. Coutre, I. Flinn, J. Burger, K. Blum, B. Grant, J. Sharman, M. Coleman, W. Wierda, Jeffrey Jones, Weiqiang Zhao, N. Heerema, A. Johnson, J. Sukbuntherng, B. Chang, F. Clow, E. Hedrick, J. Buggy, D. James, S. O'brien (2013)
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.The New England journal of medicine, 369 1
P. Thompson, W. Wierda (2016)
Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.Blood, 127 3
Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase in peripheral
M Hallek, B Cheson, D Catovsky (2012)
Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase in peripheral blood lymphocytes, 119
Rodrigo Santacruz, N. Villamor, M. Aymerich, A. Martı́nez-Trillos, C. López, A. Navarro, M. Rozman, S. Beà, C. Royo, M. Cazorla, D. Colomer, E. Giné, M. Pinyol, X. Puente, C. López-Otín, E. Campo, A. López-Guillermo, J. Delgado (2014)
The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapyHaematologica, 99
D. Case (1977)
Clinical staging of chronic lymphocytic leukemia.The Journal of the Maine Medical Association, 68 9
S. O'brien, R. Furman, S. Coutre, I. Flinn, J. Burger, K. Blum, J. Sharman, W. Wierda, Jeffrey Jones, Weiqiang Zhao, N. Heerema, A. Johnson, Ying Luan, D. James, A. Chu, J. Byrd (2016)
Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LeukemiaBlood, 128
P. Cramer, A. Chanan-Khan, G. Fraser, F. Demirkan, Rodrigo Silva, H. Pylypenko, S. Grosicki, A. Janssens, A. Goy, J. Mayer, M. Dilhuydy, J. Loscertales, N. Bartlett, A. Avigdor, S. Rule, Steven Sun, C. Phelps, M. Mahler, M. Salman, M. Schaffer, S. Balasubramanian, A. Howes, M. Hallek (2015)
Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Blood, 126
G. Fraser, P. Cramer, F. Demirkan, Rodrigo Silva, H. Pylypenko, S. Grosicki, A. Janssens, A. Pristupa, J. Mayer, M. Dilhuydy, J. Loscertales, A. Goy, A. Avigdor, S. Rule, C. Phelps, M. Mahler, M. Salman, A. Howes, S. Balasubramanian, A. Chanan-Khan (2016)
Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.Journal of Clinical Oncology, 34
J. Byrd, R. Furman, S. Coutre, J. Burger, K. Blum, M. Coleman, W. Wierda, Jeffrey Jones, Weiqiang Zhao, N. Heerema, A. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, D. James, S. O'brien (2015)
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.Blood, 125 16
This ad hoc analysis of data from 2 clinical trials examines factors that may predict complete response in patients with chronic lymphocytic leukemia or small lymphocytic leukemia treated with ibrutinib.
JAMA Oncology – American Medical Association
Published: May 22, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.